Shisong Jiang

Professor Shisong Jiang is a globally renowned immunologist and the scientific founder of Oxford Vacmedix. He studied medicine in China before completing a PhD and postdoctoral research in immunology at the Dana-Farber Cancer Institute at Harvard University, then joining the University of Oxford's Department of Oncology. It was during his time at Oxford that he pioneered the concept of Recombinant Overlapping Peptides — a fundamentally new way of designing therapeutic vaccines that generate broad, powerful killer T-cell immunity against cancers.

Recognising the transformative potential of ROP technology, Professor Jiang co-founded Oxford Vacmedix in 2012 as a spinout from Oxford University. As Chief Scientific Officer, he has led the scientific development of the company's two lead immunotherapies: OVM-200, which targets survivin — a protein overexpressed in over 90% of solid tumours — and OVM-100, a therapeutic HPV vaccine targeting cervical and head-and-neck cancer. OVM-200 has now completed Phase 1 clinical trials at leading UK hospitals, demonstrating excellent safety and strong immune responses.

Professor Jiang's ROP technology is distinguished by its universality: applicable across virtually all HLA types, it makes truly off-the-shelf cancer vaccines possible — dramatically reducing cost and complexity compared to personalised approaches. Oxford Vacmedix has raised over £3 million in its most recent round and is advancing towards Phase 2 trials, with backing from investors including Prostate Cancer Research and Dx&Vx.